Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists
Expert Review of Clinical Pharmacology · 2024
DOI: 10.1080/17512433.2024.2417655 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Marta Waliszewska-Prosół und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Wroclaw Medical University, Wroclaw, Poland. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists, Calcitonin Gene-Related Peptide, Receptors, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 116 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: The discovery of the role of the calcitonin gene-related peptide (CGPR) in migraine pathogenesis ushered in a new era in headache medicine. This evidence led to the development of small-molecule CGRP receptor antagonists and monoclonal antibodies targeting either CGRP or its receptor. AREAS COVERED: We will present selected aspects of the role of CGRP in the pathogenesis of migraine, the efficacy of CGRP-targeted treatment, and the still-open questions regarding the practical application of CGRP antagonists in headache medicine. EXPERT OPINION: CGRP-targeting drugs represent a transformative approach to migraine treatment, offering superior efficacy and tolerability compared to traditional therapies, they are a helpful addition to the treatment arsenal but also have their flaws and require further observation. Their availability provides new hope for migraine patients, particularly those who have not responded adequately to conventional treatments. Future directions for migraine care planning, especially for chronic migraine and medication-overuse headache, should include universal access to these specific and effective forms of therapy to prevent complications from the disease and its negative effects in many aspects of a patient's life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Wroclaw Medical University, Wroclaw, Poland.
- Department of Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin, Germany.
- Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany.
- Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury, Olsztyn, Poland.
- School of Health, Unitelma Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Marta Waliszewska-Prosół, Bianca Raffaelli, Marcin Straburzyński, Paolo Martelletti
Zitieren
APA
Waliszewska-Prosół, M., Raffaelli, B., Straburzyński, M., & Martelletti, P. (2024). Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2417655
Vancouver
Waliszewska-Prosół M, Raffaelli B, Straburzyński M, Martelletti P. Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2417655
BibTeX
@article{WaliszewskaPros2024,
author = {Waliszewska-Prosół, Marta and Raffaelli, Bianca and Straburzyński, Marcin and Martelletti, Paolo},
title = {Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
doi = {10.1080/17512433.2024.2417655}
}
EUVIMED